Jordyn Sava is an editor for Targeted Oncology.
Early Clinical Activity Observed With TAC01-HER2 in HER2-Positive Solid Tumors
October 20th 2022TAC01-HER2 elicited encouraging safety and clinical activity in patients with HER2-positive solid tumors with no dose limiting toxicities, cytokine release syndrome, or immune effector cell-associated neurotoxicity observed.
Adding Palbociclib to Endocrine Therapy Fails to Improve iDFS in ER+ Breast Cancer
October 18th 2022During the 2022 October ASCO Plenary Series, an analysis from the PALLAS trial revealed there to be no invasive disease-free survival benefit derived with palbociclib added to endocrine therapy in ER-positive breast cancer.
Olaparib Shows OS Improvement in gBRCA-Mutated Breast Cancer in the OlympiA Trial
October 17th 2022The second interim analysis of OlympiA showed olaparib to improve overall survival, invasive-disease-free survival, distant-disease-free survival, and revealed no new safety signals in patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer.
Lasofoxifene Shows Clinical Significance in ESR1+, ER+/HER2- Metastatic Breast Cancer
October 17th 2022In an interview with Targeted Oncology, Matthew P. Goetz, MD, discussed these recent data on estrogen receptor mutations in patients with breast cancer. He also provided expert insight on the results of ELAINE-1.
Sequential Immunotherapy and Targeted Therapy Shows OS Benefit in BRAF+ Melanoma
October 12th 2022Three different sequencing schemas for immunotherapy followed by targeted therapy in patients with BRAF V600-mutant melanoma have shown positive survival outcomes and safety consistent with results from prior studies.
PRESERVE 2 Trial of Trilaciclib Completes Enrollment of Patients With Metastatic TNBC
October 12th 2022The PRESERVE 2 trial evaluating trilaciclib in patients with metastatic breast cancer has finished enrolling patients. Results from the interim analysis of the trial is expected in the second half of 2023.
First Patient With B-NHL or CLL Treated With MB-106 in Phase 1/2 Study
October 10th 2022The phase 1/2 clinical trial of MB-106 is demonstrating high efficacy, durable responses, and a favorable safety profile as the first patient treated did not experience cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome
Magrolimab Development Continues for the Treatment of AML and MDS
October 4th 2022In an interview with Targeted Oncology, Naval G. Daver, MD, discussed the approved and investigational CD47 monoclonal antibodies for patients with acute myeloid leukemia and myelodysplastic syndrome and where research is taking this space.
Integrating CAR T-Cell Therapy Into Community Oncology Practices
October 3rd 2022In an interview with Targeted Oncology, Peter A. McSweeney discussed the ways in which community oncology centers are implementing chimeric antigen receptor T-cell therapy into their practice and the challenges that come with it.